论文部分内容阅读
目的 研究中药益肝康对CCl4 和猪血清 (PS)所致的肝纤维化的防治作用。方法 采用CCl4 和PS 1 0周法制作SD大鼠肝纤维化模型 ,用中药益肝康治疗 1 4周。预防组在制模前 4周即开始预防用药 ,于制模结束时停止用药 ;治疗组在制模结束前 4周开始用药治疗 ,于制模结束后 1 0周停止用药。设正常对照组和模型对照组。进行Mas son染色肝组织病理切片检查 ,采用计算机图像分析系统对结果进行分析。结果 在两种模型中 ,对照组、预防组、治疗组假小叶数目、纤维间隔数目间的差别均有显著性意义 (P <0 0 5) ;PS造模各组肝组织纤维间隔宽度间的差别有显著性意义 (P <0 0 5 ,造模结束后第 4周者除外 )。结论 益肝康对上述两种造模方法所致的肝纤维化均具有明显的防治作用。造模前 4周即开始预防用药比造模结束前 4周开始治疗用药更能有效地防止大鼠肝纤维化的形成。
Objective To study the preventive and therapeutic effects of Yigangan on hepatic fibrosis induced by CCl4 and swine serum (PS). Methods SD rat liver fibrosis model was made by CCl4 and PS 10 weeks method, and treated with Yigangan for 14 weeks. The prophylaxis group started to prevent the medication 4 weeks before the model making and stopped the medication at the end of the model making. The treatment group began to take the drug treatment 4 weeks before the end of the modeling, and the drug was stopped 10 weeks after the model was finished. Normal control group and model control group. Mas son staining of liver biopsy, the use of computer image analysis system to analyze the results. Results In the two models, there were significant differences in the number of fake leaflets and the number of fiber septa between control group, prophylaxis group and treatment group (P <0.05) The differences were significant (P <0.05, except for the 4th week after modeling). Conclusion Yigankang had obvious preventive and therapeutic effects on the liver fibrosis caused by the above two modeling methods. 4 weeks before modeling, prophylaxis began to prevent the formation of hepatic fibrosis in rats 4 weeks before the end of treatment.